Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXAQZ0)

Drug Name
2-(4-bromo-2-tert-butylphenoxy)acetic acid Drug Info
Synonyms
2-[4-BROMO-2-(TERT-BUTYL)PHENOXY]ACETIC ACID; 425372-86-7; 2-(4-bromo-2-tert-butylphenoxy)acetic acid; (4-bromo-2-tert-butylphenoxy)acetic acid; CHEMBL386348; 2-(4-bromo-2-(tert-butyl)phenoxy)acetic acid; 2-[2-(tert-butyl)-4-bromophenoxy]acetic acid; CBMicro_046462; AC1LEXUE; Oprea1_645612; Oprea1_576852; ARONIS011292; SCHEMBL12478128; CTK7J5471; BBB/316; MolPort-000-651-933; GCBNGPDJYUPSBS-UHFFFAOYSA-N; ZINC120478; KS-000042GS; ZX-AS003555; ZX-AL002245; SBB043460; STK948100; BDBM50200269; 3158AE; AKOS000273807; MCULE-9342897788
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
719761
TTD Drug ID
DMXAQZ0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [2]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [3]
Fevipiprant DM4NX0C Asthma CA23 Phase 3 [4]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [5]
AMG 853 DM973N4 Asthma CA23 Phase 2 [6]
ADC-3680 DM8GHIX Allergic rhinitis CA08.0 Phase 2 [7]
ARRY-502 DM17469 Allergic asthma CA23.0 Phase 2 [8]
QAV-680 DMIZYV1 Allergic rhinitis CA08.0 Phase 2 [9]
AP-761 DMISQOZ Asthma CA23 Phase 2 [10]
AZD1981 DMMCL9F Chronic obstructive pulmonary disease CA22 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin D2 receptor 2 (PTGDR2) TTQDMX5 PD2R2_HUMAN Inhibitor [1]

References

1 Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
2 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
3 Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
4 Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
5 CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
6 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
7 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
8 Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
9 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
11 Clinical pipeline report, company report or official report of AstraZeneca (2009).